| Primary |
| Rheumatoid Arthritis |
63.9% |
| Hypertension |
6.1% |
| Gastritis |
3.3% |
| Colitis Ulcerative |
3.1% |
| Osteoporosis |
2.6% |
| Gastric Ulcer |
2.4% |
| Diabetes Mellitus |
2.1% |
| Crohn's Disease |
1.7% |
| Musculoskeletal Pain |
1.7% |
| Pain |
1.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Seronegative Arthritis |
1.3% |
| Arthralgia |
1.2% |
| Atrial Fibrillation |
1.2% |
| Psoriatic Arthropathy |
1.2% |
| Angina Pectoris |
1.1% |
| Hyperlipidaemia |
1.1% |
| Prophylaxis |
1.1% |
| Arthritis |
1.0% |
| Cardiac Failure Chronic |
1.0% |
|
| Pyrexia |
10.5% |
| Interstitial Lung Disease |
9.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
6.6% |
| White Blood Cell Count Decreased |
6.6% |
| Liver Disorder |
5.9% |
| Rash |
5.9% |
| Pancytopenia |
5.5% |
| Stomatitis |
4.7% |
| Drug Eruption |
4.3% |
| Pneumonia |
4.3% |
| Vomiting |
4.3% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
3.9% |
| Hepatic Function Abnormal |
3.9% |
| Sepsis |
3.9% |
| Weight Decreased |
3.9% |
| Hypersensitivity |
3.5% |
| Pleural Effusion |
3.5% |
| Rheumatoid Arthritis |
3.5% |
| Glomerulonephritis Membranous |
3.1% |
| Septic Shock |
3.1% |
|
| Secondary |
| Rheumatoid Arthritis |
54.1% |
| Drug Use For Unknown Indication |
7.4% |
| Product Used For Unknown Indication |
6.6% |
| Hypertension |
5.6% |
| Ankylosing Spondylitis |
3.0% |
| Spondylitis |
2.4% |
| Crohn's Disease |
2.3% |
| Asthma |
2.1% |
| Pain |
2.0% |
| Osteoporosis |
1.7% |
| Prophylaxis |
1.7% |
| Seronegative Arthritis |
1.7% |
| Gastritis |
1.6% |
| Sjogren's Syndrome |
1.6% |
| Colitis Ulcerative |
1.5% |
| Gastric Ulcer |
1.5% |
| Psoriatic Arthropathy |
1.0% |
| Arthralgia |
0.8% |
| Colitis |
0.7% |
| Hyperlipidaemia |
0.7% |
|
| Rheumatoid Arthritis |
10.8% |
| Pyrexia |
8.6% |
| Rash |
7.2% |
| Pericardial Effusion |
6.5% |
| Pneumonia |
6.5% |
| Toxic Skin Eruption |
5.8% |
| Liver Disorder |
5.0% |
| Sepsis |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
4.3% |
| Generalised Erythema |
4.3% |
| Interstitial Lung Disease |
4.3% |
| Pleural Effusion |
4.3% |
| Agranulocytosis |
3.6% |
| Drug Hypersensitivity |
3.6% |
| Pulmonary Tuberculosis |
3.6% |
| Gastric Ulcer Haemorrhage |
2.9% |
| Hepatic Function Abnormal |
2.9% |
| Herpes Zoster |
2.9% |
| Organising Pneumonia |
2.9% |
|
| Concomitant |
| Rheumatoid Arthritis |
47.3% |
| Product Used For Unknown Indication |
18.0% |
| Hypertension |
4.4% |
| Prophylaxis |
3.8% |
| Crohn's Disease |
3.2% |
| Drug Use For Unknown Indication |
3.2% |
| Osteoporosis |
3.1% |
| Psoriatic Arthropathy |
3.0% |
| Ankylosing Spondylitis |
2.1% |
| Colitis Ulcerative |
1.6% |
| Pain |
1.5% |
| Arthritis |
1.2% |
| Gastritis |
1.1% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Rhinitis Allergic |
1.0% |
| Hyperlipidaemia |
1.0% |
| Insomnia |
1.0% |
| Depression |
1.0% |
| Blood Cholesterol Increased |
0.8% |
| Constipation |
0.7% |
|
| Pneumonia |
8.9% |
| Rheumatoid Arthritis |
8.5% |
| Vomiting |
8.1% |
| Interstitial Lung Disease |
7.4% |
| Drug Ineffective |
5.6% |
| Nausea |
5.6% |
| Pneumocystis Jiroveci Pneumonia |
5.2% |
| Injection Site Pain |
4.8% |
| Weight Decreased |
4.8% |
| Respiratory Failure |
4.4% |
| Urinary Tract Infection |
4.4% |
| Death |
4.1% |
| Hepatic Function Abnormal |
4.1% |
| Cerebral Infarction |
3.7% |
| Pyrexia |
3.7% |
| Sepsis |
3.7% |
| Pain |
3.3% |
| Skin Ulcer |
3.3% |
| Tuberculous Pleurisy |
3.3% |
| Palpitations |
3.0% |
|
| Interacting |
| Rheumatoid Arthritis |
37.5% |
| Hyperlipidaemia |
12.5% |
| Hypertension |
12.5% |
| Hypothyroidism |
12.5% |
| Pain |
12.5% |
| Pulmonary Embolism |
12.5% |
|
| Drug Interaction |
50.0% |
| Gastrointestinal Haemorrhage |
50.0% |
|
